Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial-Reference-Cited by-同舟云学术

Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial

Published:2024-08 Issue:8 Volume:25 Page:1015-1024
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Tendler Salomon,Dunphy Mark P,Agee Matthew,O'Donoghue Joseph,Aly Rania G,Choudhury Noura J,Kesner Adam,Kirov Assen,Mauguen Audrey,Baine Marina K,Schoder Heiko,Weber Wolfgang A,Rekhtman Natasha,Lyashchenko Serge K,Bodei Lisa,Morris Michael J,Lewis Jason S,Rudin Charles M,Poirier John T

Publisher

Elsevier BV

Reference27 articles.

1. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo;Saunders;Sci Transl Med,2015

2. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study;Paz-Ares;J Clin Oncol,2023

3. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer;Rudin;J Hematol Oncol,2023

4. DLL3 as an emerging target for the treatment of neuroendocrine neoplasms;Yao;Oncologist,2022

5. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study;Aggarwal;J Clin Oncol,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in cancer imaging;Trends in Cancer;2024-09

2. ImmunoPET in high-grade neuroendocrine tumours;The Lancet Oncology;2024-08

3. Von der PET-Bildgebung zur Theranostik – nuklearmedizinische Perspektiven beim kleinzelligen Lungenkarzinom;Die Onkologie;2024-07-15